# [18F]PI-2620 Phase 3 Histopathological Study

> **NCT05641688** · PHASE3 · RECRUITING · sponsor: **Life Molecular Imaging Ltd** · enrollment: 200 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** [18F]PI-2620

## Key facts

- **NCT ID:** NCT05641688
- **Lead sponsor:** Life Molecular Imaging Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05641688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05641688, "[18F]PI-2620 Phase 3 Histopathological Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05641688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*